We are a global #celltherapy company focused on developing, manufacturing and commercializing #cancer treatments. $LEGN
Joined April 2019
- Tweets 537
- Following 304
- Followers 1,118
- Likes 224
Photos and videos
At #EHA2026, we shared late-breaking data on LB2501, marking an important step in our ongoing efforts to advance cell therapy research. Hear from our leaders on the significance of this milestone and the value of bringing new scientific insights to the hematology community.
1
6
236
#LegendNews: At @EHA_Hematology, we presented Phase 1 data for LB2501, our investigational in vivo CD19/CD20 dual-targeting CAR-T therapy. Results showed clinical activity after a single infusion and a favorable safety profile to date. Read more: bit.ly/4erUIIR
6
8
289
Jun 11
At #Nerdland2026, our #LEGENDary team in Belgium helped bring the science of #CellTherapy to life through our CAR-T Showcase Experience.
Proud to support opportunities that spark curiosity, make science more accessible and highlight the potential of cell therapy for patients.
125
Jun 10
Heading to #EHA2026? Visit us at booth A5.05 to learn more about our latest advances in #CellTherapy and ongoing, innovative efforts across oncology. We look forward to connecting with the hematology community to share the science behind our work.
@EHA_Hematology
1
3
156
Sunday is #NationalCancerSurvivorsDay, a day to honor the resilience of cancer survivors everywhere. They inspire our commitment to advancing innovation for patients worldwide.
We celebrate survivors, caregivers, and the communities standing beside them.
#PatientsFirst
1
2
147
At #ASCO26, the oncology community came together to share research and advance care. Legend Biotech presented new data across our CAR-T cell therapy portfolio, including early findings in solid tumors and continued data in multiple myeloma.
#CellTherapy @ASCO
1
2
8
339
#LegendNews at #EHA2026. We’ll present initial Phase 1 LB2501 data in relapsed/refractory B-cell NHL in a late-breaking oral presentation. The abstract highlights encouraging clinical activity and a favorable safety profile.
Learn more: bit.ly/4o6cjKS
@EHA_Hematology
7
11
807
#LegendNews: At #ASCO26, we shared new data highlighting the potential of CAR-T cell therapy, including encouraging early Phase 1 results for investigational LB2102 in solid tumors.
Read more: bit.ly/4dILIA6
#Oncology #CellTherapy
1
1
9
939
One theme emerging across conversations this week is how quickly oncology research continues to evolve and where next-generation innovation could help shape the future of treatment.
1
2
146
Following the LB2102 announcement, CEO Ying Huang shares his perspective on the importance of continued research in solid tumors.
7
162
May 31
Quick pulse check from the floor at #ASCO26: We asked attendees what conversations are shaping the future of oncology right now. A lot of answers started with the same idea: momentum.
1
9
434
May 31
Another question we asked attendees: “What gives you hope in oncology innovation right now?” #ASCO26
1
3
161
May 31
The best part of #ASCO26 continues to be the exchange of ideas, perspectives, and experiences happening across the community. More conversations ahead tomorrow.
1
128
May 30
The energy at #ASCO26 feels different this year. More conversations around earlier intervention. More momentum behind cell therapy. More urgency around what comes next. A few reflections from the Legend team onsite today.
1
2
6
324
May 30
We asked a few of our leaders what they’re most excited about heading into the weekend. Their response wasn’t a single study or session. Instead, it highlighted the momentum across the oncology community. #ASCO26
1
3
8
186